checkAd
    Startseite > Aktien > Genelux Corporation > Nachrichten
    Genelux Corporation Aktie
    3,6500
     
    USD
    -4,95 %
    -0,1900 USD
    Letzter Kurs 02:00:00 Nasdaq
    3,6500
     
    USD
    100 STK
    Geldkurs 07.05.24
    3,6600
     
    USD
    1.300 STK
    Briefkurs 07.05.24
    ISIN: US36870H1032 · WKN: A3DQF9 · SYM: GNLX · USA

    Neueste Nachrichten

    Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    01.04.24 · globenewswire · Genelux Corporation
    Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
    27.11.23 · globenewswire · Genelux Corporation
    Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
    14.11.23 · globenewswire · Genelux Corporation
    Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    14.09.23 · globenewswire · Genelux Corporation
    Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
    07.09.23 · globenewswire · Genelux Corporation
    Genelux Corporation Announces New Chief Financial Officer
    28.08.23 · globenewswire · Genelux Corporation
    Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
    14.08.23 · globenewswire · Genelux Corporation
    Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
    02.08.23 · globenewswire · Genelux Corporation
    Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
    20.07.23 · globenewswire · Genelux Corporation
    Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
    10.07.23 · globenewswire · Genelux Corporation
    Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC
    29.06.23 · globenewswire · Genelux Corporation
    Genelux Corporation Set to Join the Russell 3000 and Russell 2000 Indexes Effective June 26, 2023
    22.06.23 · globenewswire · Genelux Corporation